Insulet Corporation $PODD Shares Sold by Allspring Global Investments Holdings LLC

Key Points

• Allspring Global Investments Holdings LLC reduced its stake in Insulet Corporation by 38.7%, owning 3,206 shares after selling 2,023 shares during the second quarter.
• Insulet reported a $1.17 EPS for the quarter, exceeding forecasts of $0.92, along with a year-over-year revenue increase of 32.9%, totaling $649.10 million.
• Several analysts have upgraded their ratings for Insulet, with Royal Bank of Canada increasing the target price to $365.00 and Zacks Research moving from a "hold" to a "strong-buy" rating.

Allspring Global Investments Holdings LLC lessened its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 38.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,206 shares of the medical instruments supplier's stock after selling 2,023 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in Insulet were worth $962,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. CWM LLC raised its stake in shares of Insulet by 8.3% in the 2nd quarter. CWM LLC now owns 4,370 shares of the medical instruments supplier's stock valued at $1,373,000 after purchasing an additional 336 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its stake in shares of Insulet by 15.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,653 shares of the medical instruments supplier's stock valued at $4,918,000 after purchasing an additional 2,043 shares in the last quarter. Apollon Wealth Management LLC raised its stake in shares of Insulet by 16.6% in the 2nd quarter. Apollon Wealth Management LLC now owns 1,262 shares of the medical instruments supplier's stock valued at $396,000 after purchasing an additional 180 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new stake in shares of Insulet in the 2nd quarter valued at about $448,000. Finally, Trust Co. of Toledo NA OH acquired a new stake in shares of Insulet in the 2nd quarter valued at about $35,000.

Insulet Price Performance

NASDAQ PODD opened at $329.22 on Thursday. Insulet Corporation has a 52 week low of $226.50 and a 52 week high of $353.50. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a market cap of $23.17 billion, a price-to-earnings ratio of 100.07, a price-to-earnings-growth ratio of 2.75 and a beta of 1.40. The company has a 50-day moving average price of $327.45 and a two-hundred day moving average price of $303.46.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same quarter in the prior year, the firm earned $0.55 EPS. Insulet's quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on PODD shares. Royal Bank Of Canada upped their target price on shares of Insulet from $350.00 to $365.00 and gave the company an "outperform" rating in a research note on Friday, October 10th. Zacks Research upgraded shares of Insulet from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, October 14th. Jefferies Financial Group reiterated a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Rothschild & Co Redburn increased their price objective on shares of Insulet from $350.00 to $370.00 and gave the stock a "buy" rating in a research note on Friday, October 3rd. Finally, Piper Sandler increased their price objective on shares of Insulet from $320.00 to $360.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $352.11.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares of the company's stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.